Document is current

Article History

Received: 3 July 2024

Accepted: 4 October 2024

First Online: 11 October 2024

Declarations

:

: All authors have read and agreed to the published version of the manuscript. D.M. is a consultant for, and has equity in, BiomeSense, Inc. The terms of these arrangements have been reviewed and approved by the University of California, San Diego, in accordance with its conflict of interest policies. Rob Knight is a scientific advisory board member, and consultant for BiomeSense, Inc., has equity and receives income. He is a scientific advisory board member and has equity in GenCirq. He is a consultant for DayTwo, and receives income. He has equity in and acts as a consultant for Cybele. He is a co-founder of Biota, Inc., and has equity. He is a cofounder of Micronoma, and has equity and is a scientific advisory board member. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.

: The study was approved by the Mahidol University Central Institutional Review Board (MU-CIRB) (Approved protocol number MU-CIRB 2018/181.1309 and COA No. MU-CIRB 2018/184.2610). MU-CIRB is in full compliance with International Guidelines for Human Research Protection including Declaration of Helsinki, The Belmont Report, CIOMS Guidelines and the International Conference on Harmonization in Good Clinical Practice (ICH-GCP). Informed consent was obtained from all subjects involved in the study.